Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease
- Conditions
- Parkinson Disease
- Interventions
- Registration Number
- NCT03959540
- Lead Sponsor
- Bial - Portela C S.A.
- Brief Summary
The purpose of this study is to describe the safety and efficacy of opicapone plus standard of care in elderly patients with PD in the real-world setting
- Detailed Description
This will be a multinational, multicentre, prospective non-interventional study in elderly patients with PD. Approximately 100 patients with PD will be recruited by specialists from approximately 37 sites in European countries. The total enrolment period will be one year, and each patient will be followed for up to one year after enrolment.
PD patients with end-of-dose motor fluctuations suitable for additional treatment optimization will be included in the study and split into 2 cohorts:
* Cohort 1: 50 patients; standard of care (including L-DOPA) + starting opicapone
* Cohort 2: 50 patients; standard of care (including L-DOPA Data will be collected at baseline (date of enrolment), 1 month, 3 months, 6 months, 9 months, and 12 months after enrolment.
This non-interventional study does not recommend the use of any specific treatments. Use of opicapone and of standard of care are only driven by the physician's decision.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 39
- Patient or legally acceptable representative willing and able to provide informed consent as mandated by local regulation
- Patient with clinical diagnosis of idiopathic PD (excluding non-idiopathic PD: atypical Parkinsonism, secondary [acquired or symptomatic] Parkinsonism, Parkinson-plus syndrome)
- Patient with age >=75 years at enrolment
- Patient with end-of-dose motor fluctuations suitable for additional treatment optimization
- Patient concurrently participating in any clinical trial
- Patient who used tolcapone or opicapone previously
- For the patient who starts opicapone: concomitant treatment with entacapone or tolcapone is not allowed
- Patient with any contraindications to Ongentys use
- Patient with any concomitant medical condition that could interfere with study assessments
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cohort 1 Levodopa (L-DOPA) + Standard care Standard of care (including L-DOPA) + starting opicapone Cohort 2 Levodopa (L-DOPA) + Standard care Standard of care (including L-DOPA) Cohort 1 Opicapone Standard of care (including L-DOPA) + starting opicapone
- Primary Outcome Measures
Name Time Method Percentage of patients having at least one Adverse Event (AE) through study completion, an average of 1 year All AEs reporting
- Secondary Outcome Measures
Name Time Method Unified Parkinson's Disease Rating Scale (UPDRS) at baseline, Follow-up visit at 6,12 months change from baseline at each follow-up visit for each of the 4 sections and for the total score (from 0=no disability to 199=total disability).
Patients' Global Impressions of Change (PGI-C) at Follow-up visit at 1, 3, 6, 9, 12 months Percentage of patients for each item at each follow-up visit (from 1=very much improved since the initiation of treatment to 7=very much worse since the initiation of treatment).
Parkinson Disease Questionnaire (PDQ-8) at baseline, Follow-up visit at 6,12 months hange of score from baseline at each follow-up visit (from 0=good health to 100=poor health).
Clinical Global Impression of Improvement (CGI-I) at Follow-up visit at 1, 3, 6, 9, 12 months hange of score from baseline at each follow-up visit (from 0=good health to 100=poor health).
Montreal Cognitive Assessment (MoCA) at baseline, Follow-up visit at 6,12 months change from baseline at each follow-up visit (30-point test; score \>26 is normal).
Trial Locations
- Locations (1)
Norfolk&Norwich University Hospitals
🇬🇧Norwich, Norfolk, United Kingdom